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A B S T R A C T
Haemolysis and methaemoglobinaemia (MetHb) are rare metabolic complications that can occur in
Alkaptonuria (AKU), for which there is no curative treatment. Presented is a case of a man who had AKU, and
serves as a reminder of life-threatening complications that can occur with haemolysis and MetHb. This case
presents an opportunity to revisit important considerations relating to the investigation and treatment of hae-
molysis and MetHb with a view to raising awareness, and in doing so hopefully reducing the uniformly fatal
outcome. Additionally it is proposed that treatment of haemolysis and MetHb with nitisinone is considered as a
potentially lifesaving treatment as it is believed that reducing the concentration of circulating homogentisic acid
will reduce oxidative stress.
1. Introduction
Alkaptonuria (AKU, OMIM 203500) is a rare disorder of the tyrosine
metabolic pathway that is inherited in an autosomal recessive manner,
occurring in 1 in 250,000 people [1]. It results from a defect in the HGD
gene, which encodes homogentisate 1,2-dioxygenase (HGD, EC
1.13.11.5) [2]. The major metabolic consequence of this defect is the
significant accumulation of homogentisic acid (HGA) in circulation, and
excretion in urine. This increase in HGA is central to the pathophy-
siology of the disorder, and the deposition of a dark pigment in tissues
in a process referred to as ochronosis. The clinical manifestations of this
disease are typically observed from the third decade of life and often
severely debilitating, but are not generally considered to result in a fatal
outcome (see reference [3] for a recent review). Srsen et al. [4] con-
cluded that life span in patients with AKU is unaffected and similar
views have also led to the disease being perceived as relatively benign.
This has hindered progressing understanding the condition and devel-
oping effective disease-modifying therapies. Treatments are mostly
palliative and supportive in nature, including underutilised phy-
siotherapy, pain relief and joint replacement. Recently there has been a
major focus on the use of nitisinone for the treatment of AKU. This
competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD,
EC 1.13.11.27) is highly efficacious in reducing HGA [5–10] and has
been shown to slow the progress of ochronosis and its consequences
[11].
Less commonly observed in AKU are the life threatening acute
complications – haemolysis and or methaemoglobinaemia (MetHb). In
all 11 cases that have been reported (Table 1) in AKU the mortality rate
was 100% [12–22]. Below is a report of a recent case of haemolysis and
MetHb in a man who had AKU, and serves as a reminder of life-
threatening complications that can occur. This case presents an op-
portunity to revisit important considerations relating to the investiga-
tion and treatment of haemolysis and MetHb in the context of AKU,
with a view to raising awareness, and in doing so hopefully reducing
the uniformly fatal outcome. Moreover it enables discussion around the
potential use of nitisinone as a potentially lifesaving treatment for these
patients.
2. Case report
A 48-year old man underwent a successful uncomplicated elective
knee arthroplasty. Prior to knee surgery, haemoglobin was within the
normal reference interval (136 g/L). Three days later he presented to
hospital with myocardial tightness to his chest, this was thought to have
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been brought on by stress and renal colic pain. At this time he had low
haemoglobin (Table 2). Five days after this episode he presented to his
local hospital with pain to his left side, nausea and vomiting. He had
anaemia of unexplained origin, was jaundiced (Table 2) and had as-
cites. He was not on nitisinone or any other regular medications at the
time of presentation and did not have a history of haemolysis. At this
time he was considered to be nutritionally replete and was not on a
protein restricted diet.
Past medical history included a diagnosis of AKU five years pre-
viously, documented by increased urine HGA. He also had a history of
asthma and an umbilical hernia (~4 cm). His right kidney was reduced
in size by 10 cm on ultrasonography, and had previous episodes of renal
colic and renal stones (three months previously serum creatinine was
93 μmol/L, eGFR>60 mL/min/1.73 m2 using an enzymatic creatinine
assay).
Eight months prior to this acute presentation the patient completed
their participation in a clinical trial (Suitability Of Nitisinone in AKU 2
(SONIA-2), ClinicalTrials.gov Identifier: NCT01916382) evaluating a
disease modifying treatment for his AKU and required him to take
10 mg daily nitisinone over a four-year period (urinary HGA con-
centrations in this patient pre- and four years post nitisinone were
48,447 and 200 μmol/24 h, respectively (personal communication
Ranganath LR), reference range < 2.92 μmol/24 h [24]). Following
the clinical trial funding was not available to continue treatment with
nitisinone; nitisinone was not made available as part of the clinical trial
upon its termination and this was conveyed to patients through a pa-
tient information sheet when they were enrolled. This was because the
patients were not local and came from all around Europe and also from
Jordan, making it impossible to administer nitisinone safely with the
required metabolic and dietetic support and monitoring. It is presumed
that HGA returned to pre-nitisinone concentrations (concentration not
measured), based on our experience in the National AKU Centre in the
United Kingdom, where previous high levels of HGA in serum and urine
return by two weeks of stopping nitisinone, in keeping with the known
Table 1
Summary of cases of the acute haematological complications observed in patients with AKU reported in the literature.
Adapted from Davison et al. [23].
Age (yrs)
Gender
Primary illness Trigger MetHb present/max
concentration (%)
Treatment Outcome Reference
50
Male
Arthropathy
Type 2 diabetes
CKD
Exacerbation of COAD
Metabolic acidosis
Haemolysis
Yes
34
Methylene blue Death [12]
66
Female
Aortic valve surgery
COAD
Hereditary telangiectasias
Diabetes
AKI
Sepsis
Yes
No value reported
Unknown Death [13]
59
Male
CKD Exacerbation of CKD
Metabolic acidosis
Haemolysis
Sepsis
Yes
29.9
Haemodialysis
Methylene blue
Vitamin C
Transfusion
Death [14]
79
Male
Arthropathy AKI
Sepsis
Yes
27.9
Transfusion
Vitamin C
Death [15]
24
Male
CKD
Hypertension
Epilepsy
Exacerbation of CKD
Haemolysis
Metabolic acidosis
No Haemodialysis/filtration
N-Acetyl cysteine
Vitamin C
Transfusion
Death [16]
50
Female
None AKI
Sepsis
Yes
26.8
Haemodialysis
Methylene blue
Transfusion
Death [17]
27
Male
CKD
Renal transplant
Aortic insufficiency
?Erythropoeitic protoporphyria
Haemolysis
Thromocytopenia
Acute liver failure
No Haemodialysis
Antibiotics
Transfusion
Death [18]
72
Female
Diabetes mellitus
Gastric ulcers
Ischaemic heart disease
Arthropathy
AKI
Dehydration
Yes
43.6
Methylene blue
Ascorbic acid
Renal replacement
therapy
Transfusion
Death [19]
63
Male
CKD
Hypertension
Urosepsis
Hydronephrosis
Calculi
Exacerbation of CKD
Metabolic acidosis
Haemolysis
Yes
25.1
Haemodialysis/filtration
N-Acetyl cysteine
Vitamin C
Transfusion
Death [20]
63
Female
1 week history of anorexia, nausea,
abdominal pain
AKI
Haemolysis
Not known to have AKU, diagnosed at
post mortem
Yes
No value reported
Plasmaphoresis
Exchange transfusion
Death [21]
60
Female
ESRF
Arthropathy
Mitral valve replacement
Anaemia
3 day history of weakness
Anaemia
Yes
24.5
Exchange transfusion
Methylene blue
Haemodialysis
Antibiotics
Death [22]
48
Male
Asthma
Umbilical hernia
Renal stones
Knee arthroplasty
Pain to left side
Nausea and vomiting
Ascites
Anaemia
Jaundice
Yes
>30
Haemodialysis
Vitamin C
Death Current case
CKD – chronic kidney disease; AKI – acute kidney injury; COAD – chronic obstructive airways disease; MetHb – methaemoglobin; ESRF – end stage renal failure. All
bold text represent abnormal results - outside of the reference interval.
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half-life of 54 h. Whilst participating in the SONIA-2 clinical trial he
presented with several episodes of renal stones (1–3 stones on four
occasions), and despite intermittent renal impairment (serum creati-
nine based on Jaffe based assay varied from 90 to 131 μmol/L between
November 2014 to October 2018) secondary to the renal stones, he did
not develop any haematological complications (haemoglobin con-
centrations ranged from 148 to 160 g/L between November 2014 to
October 2018). The severity of AKU in this patient was assessed using
the AKU severity score index (AKUSSI) [25] during the SONIA-2 clinical
trial. His overall AKUSSI score (includes a score for joint, spine and
clinical) was 104 before starting nitisinone and 138 following 4 years of
treatment with nitisinone, showing the severity of his AKU did worsen
over this period. Recurrent renal stones contributed significantly to the
AKUSSI scores increasing during SONIA-2 in this patient (personal
communication Ranganath LR).
Laboratory tests carried out at the most recent acute presentation
showed profoundly low haemoglobin (Table 2) with a normal mean cell
volume, consistent with normocytic anaemia. Peripheral blood smear
did not reveal any abnormal cell forms (e.g. spherocytes or ellipto-
cytes). Additional laboratory tests revealed a marked elevation in LDH
and reticulocytes, with a very low haptoglobin; together confirming a
diagnosis of haemolysis (Table 2). The cause of the haemolysis at this
time was not known and the patient received a blood transfusion to
increase his haemoglobin. A few hours after admission the patient ap-
peared to deteriorate and additional laboratory investigations were
performed; Coombs test was negative, excluding autoimmune haemo-
lytic anaemia and arterial blood gas analysis (Table 3) revealed a
profound MetHb, with decreased oxyhaemoglobin and a mild acid-
aemia. Over the course of the day MetHb increased and oxyhae-
moglobin decreased; oxygen therapy was administered to combat hy-
poxia, but this did not improve his clinical picture. Additionally, the
patient had raised inflammatory markers (Table 2), suggesting an in-
fection of unknown origin. Assessment of renal function at the time
showed a disproportionate increase in urea compared to creatinine
(eGFR>60 mL/min/1.73 m2) and mild hyperkalaemia, this pre-renal
picture was thought to reflect dehydration and increased haemoglobin
breakdown. Insulin and dextrose were administered at this time to treat
the hyperkalaemia and to rehydrate the patient.
Over the course of the admission the patient was also given the anti-
oxidant vitamin C (1 g in 5 mL water) and haemodialysis to reduce the
metabolic consequences of haemolysis and oxidative stress. This was
unsuccessful and the patient deteriorated further; with MetHb and
lactate increasing to>30% and>17 mmol/L, respectively (Table 3).
Pre-terminally, the patient became markedly hyperkalaemic and hy-
perphosphataemic, possibly secondary to red blood cell break down and
further deterioration of renal function. In an attempt to combat this the
patient underwent further haemodialysis and had a repeat blood
transfusion. Unfortunately the patient did not respond and went into
multi-organ failure, and passed away soon after.
3. Discussion
Haemolysis and MetHb are life threatening acute complications that
can occur in AKU as a consequence of increased oxidative stress.
Currently there are no guidelines or best practice recommendations
available for the management of these patients. Outside of AKU the
investigation and management of these complications are well docu-
mented [26–28].
Sadly, this is the sixth case report of a patient presenting acutely
with both haemolysis and MetHb in a patient with AKU, and like all
other cases in the literature it presented a challenge both in the context
of diagnosis and management. There is little to be gained from an ex-
tensive comparison between the case presented and those previously
reported to have haemolysis and or MetHb. It is curious however to
note that in only 5 of 11 cases both haemolysis and MetHb were re-
ported [12–14,20,21].
HGA is central to the metabolic consequences described above and
it has been purported that it is converted to ‘soluble melanins’, which
create a pro-oxidant environment acting as a catalyst for oxidative
stress in AKU [29–33]. Additionally it has been demonstrated that
tissue injury can be induced by benzoquinone acetic acid (BQA), a
product of the oxidation of HGA by polyphenol oxidase. The formation
of BQA is likely to have a role in the formation of MetHb as it has be
shown that quinone imine compounds are involved in the formation of
MetHb [34]. Recently advanced oxidation protein products have also
been shown to be increased in AKU, providing further evidence of
Table 2
Summary of abnormal biochemistry and haematology blood results from the
acute admission to hospital.
Test Reference interval 5 Days
before
admission
Day of
admission
1 Day after
admission
Haemoglobin 118–148 g/L 98 81
Reticulocytes 0.50–1.50% 6.4
Bilirubin < 21 μmol/L 9 35 48
ALT <35 U/L 69 29
AST <45 U/L 45 57
LDH <250 U/L 2632 2498
Haptoglobin 0.32–2.5 g/L <0.32 0.12
Total calcium 2.2–2.6 mmol/L 2.30 2.15
Phosphate 0.8–1.5 mmol/L 1.48 2.06
Sodium 133–146 mmol/L 144 132 140
Potassium 3.5–5.3 mmol/L 4.0 5.9 6.5
Urea 2.5–7.8 mmol/L 12.1 35.6 26.3
Creatininea 50–130 μmol/L 145 121 91
eGFR (CKD-
EPI)
> 60 mL/min/1.73 m2 45 61 69
C-Reactive
protein
< 5 mg/L 130 158
Procalcitonin 0.05–0.1 ng/mL 3.01
All results in bold text are outside of the reference interval. Only abnormal
results are included in this table despite other investigations being performed.
a Creatinine measurements performed using an enzymatic essay.
Table 3
Summary of arterial blood gas results from the acute admission to hospital.
Blood gas measurement Reference interval Day of admission (time in 24 h format) 1 Day after admission
07:21 8.23 9.53 12.05 14.05 17.48 19.59 23.22 17.54 22.42
pH 7.34–7.44 7.32 7.33 7.43 7.41 7.43 7.43 7.38 7.43 7.17 <7.0
pCO2 4.7–6.0 kPa 4.0 3.9 3.7 3.9 3.7 3.5 4.0 3.6 2.9 4.7
pO2 11.3–14.0 kPa 9.6 10.4 10.5 16.7 24.4 23.7 12.5 13.6 15.2 16.1
Oxyhaemoglobin 96–99% 73.3 70.6 69.1 67.3 60.8 60.0 63.6 59.8 70.2 65.3
Carboxyhaemoglobin <1.5% 4.2 3.7 3.1 1.0 0.7 2.0 1.9 3.7 1.0
Methaemoglobin <1.5% 19.5 23.6 25.8 29.6 >30 >30 >30 >30 >30 >30
Oxygen saturation 96–99% 96.1 97.1 98.2 100 100 100 100 100 100 100
Lactate 0.5–2.2 mmol/L 0.6 0.5 0.6 0.9 1.6 2.1 1.9 2.8 >17.0 >17.0
All results in bold text are outside of the reference interval.
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oxidative stress [35–37]. However, an increase in HGA alone is unlikely
to be the cause of MetHb and or haemolysis, as there are a number of
patients with renal impairment in AKU who never seem to develop
MetHb and haemolysis. It is far more probable that a pre-existing dis-
turbed redox status (genetic or acquired) could provide a pro-oxidant
environment. As previously reviewed [23], there are several factors
known to favour oxidative stress, including (i) acute kidney injury (AKI)
and AKI on background of chronic kidney disease (CKD), (ii) vitamin
and trace element deficiencies and (iii) genetic deficiencies in the red
blood cell membrane (e.g. spherocytosis) or enzymes (e.g. glucose-6-
phosphate dehydrogenase (G6PD)). In the case presented the patient
had a long history of renal stones, but no history of severe AKI and or
CKD. Common to all previous cases is that all patients had AKI, in some
cases this was a new presentation and in others it occurred on a
background of CKD. An additional consideration in the patient pre-
sented is the impact that the surgery (performed five days before pre-
sentation) may have had on renal function. Whilst surgery was per-
formed without complication, it is well known that surgery causes
increased catabolic stress and may be worsened by blood loss and or
dehydration, thus impairing renal function. The impact of this is likely
to be magnified in a patient with AKU as the kidney plays a critical role
in both the elimination and secretion of HGA from the body [38].
Six of 11 patients also presented with sepsis [13,14,16,17,20,22]
and the case presented herein also had an infection of unknown origin,
which may have aggravated their renal function further due to an in-
creased catabolism, leading to an increased flux down the tyrosine
metabolic pathway resulting in increased HGA production, further
contributing to oxidative stress.
In all 11 cases (Table 1), and the case presented here, HGA was not
measured at the time of the acute presentation, but is presumed to have
been increased as kidney function was impaired and patients were not
on HGA-lowering treatment; the actual measurement of HGA in this
syndrome has never been documented.
Together the accumulation of uraemic toxins and HGA are likely to
have increased oxidative stress. It is noteworthy that the measurement
of creatinine using enzymatic assays is unreliable and can lead to an
under estimation in creatinine results and therefore an overestimation
of estimated glomerular filtration rate [39]. It is the authors' re-
commendation that creatinine based measurements for the assessment
of renal function, in AKU generally and more so when much higher
concentrations are suspected following renal failure, should be done
using a Jaffe based colorimetric assay as they were when the patient
participated in the SONIA-2 clinical trial.
Common to all cases including this one is that vitamin and trace
element levels were not evaluated, nor were red cell enzyme defects
(e.g. G6PD) assessed. If such trace element deficiencies were to be
uncovered, it could also lend itself to therapeutic intervention. It is
much harder to anticipate the presence of genetic abnormalities of red
cell predisposing to haemolysis, but these are an important considera-
tion and should be borne in mind.
Parenteral iron, repeated blood transfusions and haemodialysis are
also thought to contribute to oxidative stress and together with the
factors mentioned above may overwhelm the endogenous anti-oxidant
capacity of the body leading to haemolysis and MetHb. In the case
presented the patient received two blood transfusions and haemodia-
lysis. Both modes of treatment have been utilised in the majority of
cases reported in AKU patients with haemolysis and or MetHb without
success, despite their potentially beneficial effects in treating hy-
perkalaemia and anaemia, respectively.
The only anti-oxidant therapy trialled in the case presented was
vitamin C. While vitamin C is an important substrate required for anti-
oxidant defence mechanisms (i.e. reduction of thioredoxin and glu-
tathione) it is only a small part of a somewhat complex anti-oxidant
system. Moreover caution has to be taken in using vitamin C as it can
induce haemolysis in patients with G6PD deficiency [40]. Other po-
tential anti-oxidant treatment options not utilised in this patient include
methylene blue and n-acetyl-cysteine. The rationale for using methy-
lene blue is that it reduces iron in haemoglobin back to its oxygen
carrying state Fe2+ thus improving the delivery of oxygen and reducing
oxidative stress. N-Acetyl-cysteine has also be trialled previously cases
reported [15,20] in an attempt to reduce glutathione and reduce oxi-
dative stress, but both have been used without success in previous re-
ported cases.
It is clear from this case and those that have been previously re-
ported that there is limited awareness of the life threatening nature of
acute haemolysis and or MetHb in AKU, and that all standard treat-
ments are not effective enough to save an AKU patients life. So what are
we missing? The biggest metabolic perturbation observed in AKU is the
accumulation of HGA and thus if the additional ‘insult’ for the hae-
matological complications in AKU is the formation of pro-oxidants as a
consequence of HGA accumulating, then the inhibition of its formation
should be a potential lifesaving treatment. As alluded to earlier nitisi-
none is a highly efficacious inhibitor of HGA through its action on
HPPD and is known to work rapidly (i.e. 60% decrease in circulating
HGA within 48 h on 2 mg dose (Ranganath LR, unpublished data)). In
this case (and in all other cases reported) nitisinone was not trialled,
and had been stopped eight months prior to admission as the patient
was on it as part of a clinical trial. It is difficult to prove in this patient
that stopping nitisinone after having a 10 mg daily dose caused a
progressive increase in oxidative stress and contributed to these com-
plications. Nitisinone was not used in this case because of the limited
availability and its unproven efficacy in the setting of acute haemolysis
and MetHb, but in our opinion, this should not be a barrier to its use.
Nitisinone is widely available in most parts of the World easily as it is
used as life-saving therapy in hereditary tyrosinaemia 1 (OMIM
276700), where it is the current standard of care. It should be possible
to work with the local paediatric community to obtain nitisinone on a
compassionate emergent basis in such situations. The key is to consider
this potentially lifesaving treatment in the context of unexplained
anaemia, deterioration in renal function and suboptimal antioxidant
defence mechanisms. Only by using nitisinone in this scenario in AKU
can we prove that nitisinone is the answer to what is otherwise a uni-
formly fatal outcome.
3.1. Learning points
• A drop in haemoglobin/unexplained anaemia in AKU should lead to
methaemoglobin measurement; this biochemical assay is widely
available, rapid and reliable thus facilitating a rapid diagnosis.
• A Jaffe colorimetric assay for the measurement of creatinine should
be used to assess renal function (eGFR) in AKU on an annual basis
and not an enzymatic assay, to avoid complacency.
• Nitisinone should be ordered urgently through the local paediatric
community and if necessary by contacting the manufacturers
(Swedish Orphan Biovitrum) to administer to the patient as a po-
tentially lifesaving treatment.
• Patients with AKU should have antioxidant status assessed, in-
cluding the measurement of the trace elements copper, zinc and
selenium and be screened for deficiency in G6PD deficiency as this is
risk factor for haemolysis.
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